Taking the pathological characteristics of the chordoma TME into account, we designed a CAR-T-cell preparation, B7–H3 CAR-T/IL-7, that not only recognizes the chordoma-specific antigen B7–H3 but also enhances the anti-tumor capacity of CAR-T cells by secreting IL-7. This evidence concerns the gene IL7 and chordoma.